At close: 4:00:01 PM EST
After hours: 5:44:25 PM EST
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Cash Flow
-33,678.0000
-32,965.0000
-31,056.0000
-24,308.0000
-20,601.0000
Financing Cash Flow
40,376.0000
40,033.0000
10,000.0000
36,814.0000
263.0000
End Cash Position
27,060.0000
25,660.0000
18,592.0000
39,648.0000
27,142.0000
Issuance of Capital Stock
--
--
--
6,814.0000
263.0000
Issuance of Debt
40,000.0000
30,000.0000
10,000.0000
30,000.0000
--
Free Cash Flow
-33,678.0000
-32,965.0000
-31,056.0000
-24,308.0000
-20,601.0000
12/31/2020 - 9/4/2002
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
NMRA Neumora Therapeutics, Inc.
10.87
+5.33%
SLS SELLAS Life Sciences Group, Inc.
0.9201
+5.50%
ANAB AnaptysBio, Inc.
16.65
+6.80%
AVXL Anavex Life Sciences Corp.
9.18
+8.51%
CRVS Corvus Pharmaceuticals, Inc.
6.90
-6.50%
ALT Altimmune, Inc.
9.00
-0.33%
CKPT Checkpoint Therapeutics, Inc.
3.3900
-7.63%
VSTM Verastem, Inc.
4.6800
+4.46%
HUMA Humacyte, Inc.
4.3400
+5.85%
BMEA Biomea Fusion, Inc.
5.85
+3.72%